Article
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Nature - 5 Oct 2017
Lu Hezhe, Liu Shujing, Zhang Gao, Bin Wu, Zhu Yueyao, Frederick Dennie T, Hu Yi, Zhong Wenqun, Randell Sergio, Sadek Norah, Zhang Wei, Chen Gang, Cheng Chaoran, Zeng Jingwen, Wu Lawrence W, Zhang Jie, Liu Xiaoming, Xu Wei, Krepler Clemens, Sproesser Katrin, Xiao Min, Miao Benchun, Liu Jianglan, Song Claire D, Liu Jephrey Y, Karakousis Giorgos C, Schuchter Lynn M, Lu Yiling, Mills Gordon, Cong Yusheng, Chernoff Jonathan, Guo Jun, Boland Genevieve M, Sullivan Ryan J, Wei Zhi, Field Jeffrey, Amaravadi Ravi K, Flaherty Keith T, Herlyn Meenhard, Xu Xiaowei, Guo Wei
Abstract excerpt
Targeted BRAF inhibition (BRAFi) and combined BRAF and MEK inhibition (BRAFi and MEKi) therapies have markedly improved the clinical outcomes of patients with metastatic melanoma. Unfortunately, the efficacy of these treatments is often countered by the acquisition of drug resistance. Here we investigated the molecular mechanisms that underlie acquired resistance to BRAFi and to the combined therapy. Consistent...
Topics
- Animals
- Apoptosis
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Enzyme Activation
- Female
- Humans
- JNK Mitogen-Activated Protein Kinases